At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Human Behavioral Pharmacology Laboratory (HBPL) Study of the Impact of the NK1 Antagonist Aprepitant (Emend®) on Stress-Induced Cocaine and Alcohol Craving
In Brief
A Phase 2 clinical trial evaluating Placebo session 1, Aprepitant session 2 and Placebo session 1, Placebo session 2 for Cocaine Dependence and Alcohol Dependence. Completed, enrolled 13 participants across 1 site.
Detailed Summary
The proposed research will focus on investigating the determinants and consequences of CAD via measurement of physiological, behavioral and subjective effects of physiologic and psychologic stress cues in CAD volunteers in the laboratory, and through examination of the effects of the effects of Aprepitant, an NK1 antagonist, on the above effects. This study will examine the effects of the above stress cues on cocaine and alcohol craving under acute Aprepitant dosing, and under placebo conditions. The study is a within-subjects crossover design using 24 subjects.
Study Details
Timeline
Interventions
placebo in session 1, Aprepitant 80 mg in session 2, oral administration.
Placebo, one per session, oral administration